Use the keywords feature with a free QxMD account.

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Get Started

Keywords Rituxin

Rituxin

Follow Keyword ＋

JOURNAL ARTICLE

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone.

R F van Vollenhoven, I Gunnarsson, E Welin-Henriksson, B Sundelin, A Osterborg, S H Jacobson, L Klareskog

BACKGROUND: The monoclonal anti-B cell antibody rituximab (Rituxin, Mabthera) may be of benefit in antibody-driven diseases, including systemic lupus erythematosus (SLE) nephritis. PATIENTS AND TREATMENT: Two female patients with biopsy-confirmed severe and active SLE nephritis despite treatment with cyclophosphamide (CyX) were given four rituximab infusions plus two additional CyX infusions. RESULTS: Both patients tolerated the treatment well and SLE activity improved...

15794203

2004: Scandinavian Journal of Rheumatology

Make the most of Read.
Download the mobile app.

Use the keywords feature with a free QxMD account.

Rituxin

Save your favorite articles in one place with a free QxMD account.

Read

Search Tips